Literature DB >> 19328612

[Causes of death and risk factors for mortality in patients with severe chronic obstructive pulmonary disease].

Amalia Moreno1, Concepción Montón, Yolanda Belmonte, Miguel Gallego, Xavier Pomares, Jordi Real.   

Abstract

OBJECTIVE: The objective of this study was to assess the causes of death and risk factors for mortality in a cohort of patients with severe chronic obstructive pulmonary disease (COPD). PATIENTS AND METHODS: We studied 203 patients with severe COPD (forced expiratory volume in 1 second [FEV(1)] <50%), who were attended in our respiratory department day hospital (2001-2006). Clinical variables were recorded on inclusion, and clinical course and causes of death were retrospectively reviewed.
RESULTS: The mean (SD) age of patients was 69 (8) years and the mean FEV(1) was 30.8% (8.2%). One-hundred and nine patients died (53.7%); death was attributed to respiratory causes in 72 (80.9%), with COPD exacerbation being the most frequent specific cause within this category (48.3%). During follow-up, 18.7% required admission to the intensive care unit (ICU). Survival at 1, 3, and 5 years was 80%, 53%, and 26%, respectively. The multivariate analysis showed that mortality was associated with age, stage IV classification according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), cor pulmonale, and hospital admission during the year prior to inclusion. Need for admission to the ICU during follow-up was a factor independently associated with higher mortality.
CONCLUSIONS: Mortality in patients with severe COPD was high and exacerbation of the disease was one of the most frequent causes of death. Age, GOLD stage, cor pulmonale, prior admission to hospital, and need for admission to the ICU during follow-up were independent predictors of mortality.

Entities:  

Mesh:

Year:  2009        PMID: 19328612     DOI: 10.1016/j.arbres.2008.09.004

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  7 in total

1.  Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations.

Authors:  Xavier Pomares; Concepción Montón; Mateu Espasa; Jordi Casabon; Eduard Monsó; Miguel Gallego
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-09-06

2.  Dyspnea, Eosinopenia, Consolidation, Acidemia and Atrial Fibrillation Score and BAP-65 Score, Tools for Prediction of Mortality in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Comparative Pilot Study.

Authors:  Viral Sangwan; Dhruva Chaudhry; Roopa Malik
Journal:  Indian J Crit Care Med       Date:  2017-10

3.  COPD phenotypes: differences in survival.

Authors:  Julio Hernández Vázquez; Ismael Ali García; Rodrigo Jiménez-García; Alejandro Álvaro Meca; Ana López de Andrés; Carmen Matesanz Ruiz; María Jesús Buendía García; Javier de Miguel Díez
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-07-20

4.  Nebulized Colistin And Continuous Cyclic Azithromycin In Severe COPD Patients With Chronic Bronchial Infection Due To Pseudomonas aeruginosa: A Retrospective Cohort Study.

Authors:  Concepción Montón; Elena Prina; Xavier Pomares; Jose R Cugat; Antonio Casabella; Joan Carles Oliva; Miguel Gallego; Eduard Monsó
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-10-17

5.  [Risk factors for mortality in patients with chronic obstructive pulmonary disease].

Authors:  Josep Montserrat-Capdevila; Pere Godoy; Josep Ramon Marsal; Ferran Barbé-Illa
Journal:  Aten Primaria       Date:  2015-03-13       Impact factor: 1.137

6.  Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors.

Authors:  Miguel Gallego; Xavier Pomares; Mateu Espasa; Eva Castañer; Mar Solé; David Suárez; Eduard Monsó; Concepción Montón
Journal:  BMC Pulm Med       Date:  2014-06-26       Impact factor: 3.317

7.  Predictors of Hospitalized Exacerbations and Mortality in Chronic Obstructive Pulmonary Disease.

Authors:  Miguel Santibáñez; Roberto Garrastazu; Mario Ruiz-Nuñez; Jose Manuel Helguera; Sandra Arenal; Cristina Bonnardeux; Carlos León; Juan Luis García-Rivero
Journal:  PLoS One       Date:  2016-06-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.